Journal article

Effect of Calcium-Channel Blocker Therapy on Radial Artery Grafts After Coronary Bypass Surgery

Mario Gaudino, Umberto Benedetto, Stephen E Fremes, David L Hare, Philip Hayward, Neil Moat, Marco Moscarelli, Antonino Di Franco, Giuseppe Nasso, Miodrag Peric, Ivana Petrovic, John D Puskas, Giuseppe Speziale, Kyung Jong Yoo, Leonard N Girardi, David P Taggart



BACKGROUND: Few studies have evaluated the effect of chronic calcium-channel blocker therapy (CCB) on the angiographic and clinical outcome of radial artery (RA) grafts used for coronary bypass surgery. OBJECTIVES: The purpose of this study was to evaluate if CCB influences midterm clinical and angiographic outcomes of RA grafts. METHODS: Patient-level data of 6 angiographic randomized trials evaluating RA graft status at midterm follow-up were joined in this observational analysis. Cox regression and propensity score methods were used to evaluate the effect of CCB on the incidence of a composite of major adverse cardiac events (MACE) (death, myocardial infarction, and repeat revascularizati..

View full abstract


Funding Acknowledgements

The project was funded by the Department of Cardiothoracic Surgery of Weill Cornell Medicine. The funders had no role in any part the study. Dr. Benedetto was supported by The National Institute for Health Research Bristol Biomedical Research Centre (NIHR Bristol BRC). Dr. Fremes was supported in part by the Bernard S. Goldman Chair in Cardiovascular Surgery. Dr. Hare has served as part of the Advisory Board for Amgen, AstraZeneca, Merck, and Sanofi; has received lecture fess from Novartis; has received consulting fees from Pfizer; and has received research funds from Servier. Dr. Moat has served as CMO for Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This paper was presented at the 2018 American Heart Association Scientific Sessions, Chicago, Illinois. Danny Ramzy, MD, PhD, served as Guest Associate Editor for this paper.